A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT03242889 · COMPLETED
Trial details
- NCT number
- NCT03242889
- Sponsor
- Janssen Pharmaceutical K.K.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-10
- Primary completion
- 2017-11-01
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.